• 1. Aggregation-induced emission leading to two distinct emissive species in the solid-state structure of high-dipole organic chromophores?
  Felix Witte,Philipp Rietsch,Nithiya Nirmalananthan-Budau,Florian Weigert,Jan P. G?tze,Ute Resch-Genger,Siegfried Eigler,Beate Paulus Phys. Chem. Chem. Phys., 2021,23, 17521-17529
• 2. An intramolecular tryptophan-condensation approach for peptide stapling?
  Eunice Y.-L. Hui,Bhimsen Rout,Yaw Sing Tan,Kok-Ping Chan,Charles W. Johannes Org. Biomol. Chem., 2018,16, 389-392
• 3. An alkynylboronatecycloaddition strategy to functionalised benzyne derivatives?
  James D. Kirkham,Patrick M. Delaney,George J. Ellames,Eleanor C. Row,Joseph P. A. Harrity Chem. Commun., 2010,46, 5154-5156
• 4. Alternative mixtures to R-600a. Theoretical assessment and experimental energy evaluation of binary mixtures in a commercial cooler: Mélanges alternatifs au R-600a. évaluation théorique et évaluation énergétique expérimentale de mélanges binaires dans un refroidisseur commercial.
  DanielCalleja-Anta,DanielSánchez,LauraNebot-Andres,RamónCabello,RodrigoLlopis
• 5. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolidines Phenylpyrrolidines

Research Briefing on Ethanone,1-(2-phenyl-1-pyrrolidinyl)- (CAS: 328533-94-4): Recent Advances and Applications

Ethanone,1-(2-phenyl-1-pyrrolidinyl)- (CAS: 328533-94-4) is a chemical compound of significant interest in the field of chemical biology and pharmaceutical research. This compound, characterized by its unique pyrrolidinyl and phenyl substituents, has recently garnered attention due to its potential applications in drug discovery and development. Recent studies have explored its pharmacological properties, synthetic pathways, and therapeutic potential, making it a focal point for researchers aiming to develop novel bioactive molecules.

One of the key areas of investigation has been the compound's role as a precursor or intermediate in the synthesis of more complex molecules. Researchers have identified its utility in the construction of heterocyclic frameworks, which are prevalent in many FDA-approved drugs. The structural flexibility of Ethanone,1-(2-phenyl-1-pyrrolidinyl)- allows for diverse modifications, enabling the development of compounds with tailored biological activities. Recent synthetic methodologies have focused on optimizing yield and purity, with advancements in catalytic processes and green chemistry approaches.

In addition to its synthetic applications, Ethanone,1-(2-phenyl-1-pyrrolidinyl)- has been studied for its potential biological activities. Preliminary in vitro and in vivo studies suggest that derivatives of this compound may exhibit neuroprotective, anti-inflammatory, or antimicrobial properties. For instance, a 2023 study published in the Journal of Medicinal Chemistry demonstrated that certain analogs of this compound showed promising activity in modulating neurotransmitter receptors, hinting at potential applications in neurological disorders. However, further validation through clinical trials is necessary to confirm these findings.

The pharmacokinetic and toxicological profiles of Ethanone,1-(2-phenyl-1-pyrrolidinyl)- and its derivatives are also under investigation. Understanding these aspects is crucial for assessing the compound's suitability as a drug candidate. Recent computational modeling studies have provided insights into its metabolic pathways and potential interactions with biological targets, aiding in the design of safer and more effective derivatives. These studies underscore the importance of integrating in silico, in vitro, and in vivo approaches to fully characterize the compound's properties.

Looking ahead, the research community is optimistic about the potential of Ethanone,1-(2-phenyl-1-pyrrolidinyl)- to contribute to the development of new therapeutics. Collaborative efforts between academic institutions and pharmaceutical companies are expected to accelerate the translation of laboratory findings into clinical applications. Future research directions may include exploring its use in combination therapies, investigating its mechanism of action at the molecular level, and developing scalable synthetic routes for industrial production.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)